Somatic mutations in calreticulin (CALR) are present in approximately 40% of patients with
myeloproliferative neoplasms (MPN), but the mechanism by which mutant CALR is …

Recurrent somatic mutations of calreticulin (CALR) have been identified in patients
harboring myeloproliferative neoplasms; however, their role in tumorigenesis remains …

Mutations in calreticulin (CALR) are phenotypic drivers in the pathogenesis of
myeloproliferative neoplasms. Mechanistic studies have demonstrated that mutant CALR …

Recurrent mutations in calreticulin are present in∼ 20% of patients with myeloproliferative
neoplasms (MPNs). Since its discovery in 2013, we now have a more precise understanding …

Abstract Background Somatic calreticulin (CALR), Janus kinase 2 (JAK2), and
thrombopoietin receptor (MPL) mutations essentially show mutual exclusion in …

Calreticulin (CALR) frameshift mutations represent the second cause of myeloproliferative
neoplasms (MPN). In healthy cells, CALR transiently and non-specifically interacts with …

Mutations in the calreticulin gene (CALR) represented by deletions and insertions in exon 9
inducing a− 1/+ 2 frameshift are associated with a significant fraction of myeloproliferative …

Studies have previously shown that mutant calreticulin (CALR), found in a subset of patients
with myeloproliferative neoplasms (MPNs), interacts with and subsequently promotes the …

Studies have shown that mutant calreticulin (CALR) constitutively activates the
thrombopoietin (TPO) receptor MPL and thus plays a causal role in the development of …

Mutations affecting exon 9 of the CALR gene lead to the generation of a C-terminally
modified calreticulin (CALR) protein that lacks the KDEL endoplasmic reticulum (ER) …